GLSI — Greenwich Lifesciences Income Statement
0.000.00%
Last trade - 00:00- $132.47m
- $128.38m
Annual income statement for Greenwich Lifesciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 1.86 | 4.6 | 8.04 | 9.33 | 16 |
| Operating Profit | -1.86 | -4.6 | -8.04 | -9.33 | -16 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -1.86 | -4.57 | -7.83 | -8.89 | -15.8 |
| Net Income After Taxes | -1.86 | -4.57 | -7.83 | -8.89 | -15.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.86 | -4.57 | -7.83 | -8.89 | -15.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.86 | -4.57 | -7.83 | -8.89 | -15.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.147 | -0.353 | -0.606 | -0.692 | -1.21 |